Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D Plans

This study describes changes in the proportion of Medicare Part D plans requiring prior authorization for buprenorphine products before and after a 2017 FDA rquirement that the drug’s label emphasize the importance of drug treatment of opioid use disorder.

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA
Autores principales: Mark, Tami L., Parish, William, Zarkin, Gary A.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2019
Materias:
Research Letter
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6618771/
https://ncbi.nlm.nih.gov/pubmed/31287514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2019.6581
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares